Lykos Therapeutics Secures $100 Million Investment to Revolutionize Mental Healthcare

Lykos Therapeutics is thrilled to announce a significant funding milestone, having successfully raised $100 million to advance its mission of transforming mental healthcare.

As a Public Benefit Company dedicated to addressing the pressing needs in mental health treatment, Lykos is at the forefront of innovative research, focusing on investigational psychedelics to create therapeutic methodologies aimed primarily at treating conditions such as PTSD.

This robust funding will enable Lykos to enhance its research and development efforts, accelerating the discovery of novel treatments that have the potential to revolutionize patient outcomes.

Founded on decades of evidence-based research, Lykos is committed to exploring uncharted avenues in mental health solutions, and this new capital will play a pivotal role in our ongoing projects and clinical trials.

By harnessing the power of psychedelics, we aim not only to alleviate the symptoms of myriad mental health conditions but also to fundamentally shift the landscape of care for countless individuals.

As we continue our journey, we remain steadfast in our dedication to making a lasting positive impact on the lives of people, communities, and society at large.

We invite you to learn more about our mission and the exciting developments on the horizon by visiting us at www.lykospbc.com.